Blog
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
Key Points
- Interested in Rhythm Pharmaceuticals, Inc.? Here are five stocks we like better.
- IMCIVREE’s U.S. AHO launch is showing early traction: Rhythm received more than 400 patient start
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Key Points
- Interested in Recursion Pharmaceuticals, Inc.? Here are five stocks we like better.
- AI platform and partnerships: Recursion has accumulated more than 50 petabytes of multimodal
Rumble Eyes $3B AI Compute Run Rate From 250MW Power Pipeline
Key Points
- Interested in Rumble Inc.? Here are five stocks we like better.
- Quake AI is becoming Rumble’s primary growth engine, operating 22,000 GPUs for more than 50 customers. GPU utilization
Repay Eyes Faster Growth, Debt Reduction as KUBRA Builds Consumer Billing Platform
Key Points
- Interested in Repay Holdings Corporation? Here are five stocks we like better.
- Repay is broadening its consumer billing platform through the KUBRA acquisition, combining payment
Roper Technologies Lifts Outlook as AI, Software Acquisitions Fuel Growth
Key Points
- Interested in Roper Technologies, Inc.? Here are five stocks we like better.
- Roper raised its full-year outlook, increasing adjusted earnings guidance to $22.15–$22.30 per share and
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
Key Points
- Interested in RenovoRx, Inc.? Here are five stocks we like better.
- RenovoRx’s Phase III TIGeR-PaC trial is fully enrolled and had recorded 78 of 86 required events; final events are
Real Brokerage Eyes RE/MAX Deal as Agent Count Tops 36,000
Key Points
- Interested in The Real Brokerage Inc.? Here are five stocks we like better.
- Real Brokerage has surpassed 36,000 agents across the U.S. and Canada, with last-12-month revenue rising
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Key Points
- Interested in Avita Medical Inc.? Here are five stocks we like better.
- Avita Medical raised its 2026 revenue guidance to $86 million–$89 million from $80 million–$85 million after
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Key Points
- Interested in Avita Medical Inc.? Here are five stocks we like better.
- Avita Medical raised its 2025 revenue guidance to $86 million–$89 million, citing sequential growth from $17.6
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
Key Points
- Interested in Rani Therapeutics Holdings, Inc.? Here are five stocks we like better.
- Rani Therapeutics is broadening its RaniPill platform through partnerships and selective product
QuickLogic Targets Defense, Space Growth With Rad-Hard FPGA Push
Key Points
- Interested in QuickLogic Corporation? Here are five stocks we like better.
- QuickLogic is targeting aerospace, defense, space and critical infrastructure markets with discrete FPGAs
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Key Points
- Interested in Quanterix Corporation? Here are five stocks we like better.
- Quanterix is restructuring its sales organization into dedicated teams for spatial biology, Simoa products
Qualys Conference: ETM and Patch Management Drive Growth Ambitions
Key Points
- Interested in Qualys, Inc.? Here are five stocks we like better.
- ETM and Patch Management are central to Qualys’ growth strategy. ETM and CSAM rose to 12% of trailing-12-month
The Metals Company’s Big Bet Now Comes Down to a License
Key Points
- Interested in TMC the metals company Inc.? Here are five stocks we like better.
- The Metals Company faces a licensing delay to October, but investors had anticipated it, so shares
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
Key Points
- Interested in Palvella Therapeutics, Inc.? Here are five stocks we like better.
- QTORIN rapamycin delivered positive Phase III results in microcystic lymphatic malformations, with
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
Key Points
- Interested in PTC Therapeutics, Inc.? Here are five stocks we like better.
- PTC Therapeutics plans to acquire ST-920, a one-time Fabry disease gene therapy, through a competitive
People Inc. Targets MGM Deal, Buybacks as It Seeks Sales of Non-Core Assets
Key Points
- Interested in People Incorporated Common Stock? Here are five stocks we like better.
- People Inc. is prioritizing MGM and its People media business while exploring sales of non-core
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Key Points
- Interested in Pulse Biosciences, Inc? Here are five stocks we like better.
- Pulse Biosciences is advancing nanosecond pulsed field ablation (nsPFA) as a non-thermal platform for
Pagaya Targets $200M Net Income Run Rate as Lending Network Expands
Key Points
- Interested in Pagaya Technologies Ltd.? Here are five stocks we like better.
- Pagaya expects to exit the year with a $200 million GAAP net income run rate after reporting $45 million
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook
Key Points
- Interested in Progyny, Inc.? Here are five stocks we like better.
- Utilization is expected to rebound: Progyny said fertility-treatment engagement slowed more sharply than usual
Perion Network Bets on AI Platform as CTV, Retail Media Spend Accelerate
Key Points
- Interested in Perion Network Ltd? Here are five stocks we like better.
- Perion One is becoming the company’s AI-driven growth platform, with Outmax optimizing campaigns across channels
Pegasystems Touts Governed AI Workflows, Token-Free Pricing at Oppenheimer Conference
Key Points
- Interested in Pegasystems Inc.? Here are five stocks we like better.
- Pegasystems is positioning its platform for regulated, control-heavy enterprises that need predictable and
Pegasystems Highlights AI Push, Sales Reset After Soft ACV Growth
Key Points
- Interested in Pegasystems Inc.? Here are five stocks we like better.
- Pegasystems is expanding its AI capabilities through Pega Blueprint and Infinity Studio, which aim to accelerate
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Key Points
- Interested in Pacific Biosciences of California, Inc.? Here are five stocks we like better.
- PacBio lowered its revenue outlook as customers transition more slowly than expected to
Ouster Says Rev8 Lidar Gains Early Multimillion-Dollar Orders, Targets Broader Platform Growth
Key Points
- Interested in Ouster, Inc.? Here are five stocks we like better.
- Rev8 is gaining early traction, with Ouster reporting multimillion-dollar orders from new and existing customers